Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Delayed Data from NSDQ)

$4.50 USD

4.50
2,956,827

-0.08 (-1.75%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $4.50 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for BioCryst Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 391 426 511 303 138
Receivables 57 51 29 9 22
Notes Receivable 0 0 0 0 0
Inventories 29 28 16 7 0
Other Current Assets 20 13 10 6 4
Total Current Assets 496 517 566 324 164
Net Property & Equipment 8 9 9 7 7
Investments & Advances 0 18 7 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 13 7 6 4 4
Total Assets 517 550 588 335 175
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 30 30
Accounts Payable 21 14 28 19 14
Current Portion Long-Term Debt 24 0 0 0 9
Current Portion Capital Leases 2 2 2 1 1
Accrued Expenses 103 88 73 34 21
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 1 1 22 17
Total Current Liabilities 150 106 104 106 92
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 811 733 585 244 41
Non-Current Capital Leases 3 6 6 4 3
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 972 845 695 354 137
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 2 2 2 2
Capital Surplus 1,222 1,158 1,099 1,002 877
Retained Earnings -1,681 -1,455 -1,208 -1,023 -841
Other Equity 1 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -456 -295 -107 -19 38
Total Liabilities & Shareholder's Equity 517 550 588 335 175
Total Common Equity -456 -295 -107 -19 38
Shares Outstanding 204.80 186.40 178.80 176.50 148.30
Book Value Per Share -2.22 -1.58 -0.60 -0.11 0.26

Fiscal Year End for BioCryst Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 391 399 412 400
Receivables NA 57 54 58 49
Notes Receivable NA 0 0 0 0
Inventories NA 29 30 27 27
Other Current Assets NA 20 20 14 15
Total Current Assets NA 496 502 511 491
Net Property & Equipment NA 8 9 8 8
Investments & Advances NA 0 0 3 3
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 13 11 7 7
Total Assets NA 517 523 530 510
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 21 11 14 6
Current Portion Long-Term Debt NA 24 0 0 0
Current Portion Capital Leases NA 2 2 3 2
Accrued Expenses NA 103 77 75 75
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 1 2 1
Total Current Liabilities NA 150 91 94 85
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 811 833 819 747
Non-Current Capital Leases NA 3 10 6 6
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 972 934 919 838
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 2 2 2 2
Capital Surplus NA 1,222 1,206 1,192 1,177
Retained Earnings NA -1,681 -1,619 -1,583 -1,508
Other Equity NA 1 1 1 1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -456 -411 -389 -328
Total Liabilities & Shareholder's Equity NA 517 523 530 510
Total Common Equity 0 -456 -411 -389 -328
Shares Outstanding 206.10 204.80 189.40 189.40 188.90
Book Value Per Share 0.00 -2.22 -2.17 -2.05 -1.74